Physician profile
Andrea Wang
NPI 1780616680
$954.20
in general payments reported to CMS, 2019-2025
14 companies · $278 in 2025
The $278 reported for 2025 was less than what a typical Urogynecology and Reconstructive Pelvic Surgery (Obstetrics & Gynecology) provider received nationally (typical 2025 total: $413).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $148 · 2020: $20.41 · 2021: $76.89 · 2022: $103 · 2023: $127 · 2024: $201 · 2025: $278.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $498 · Education: $108.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $497.73 |
| Education | $108.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $227.19 | 2023-2024 | Veozah |
| Intuitive Surgical, INC. | $147.25 | 2025 | |
| Hologic Sales and Service, LLC | $82.33 | 2021-2025 | Aptima, Thinprep 2000 Processor, Acessa Provu System |
| Sage Therapeutics, LLC | $75.95 | 2023-2025 | Zurzuvae |
| Medtronic, INC. | $67.33 | 2022-2023 | Interstim |
| Coopersurgical, INC. | $65.89 | 2019 | |
| Abbvie INC. | $56.30 | 2019-2021 | |
| Myovant Sciences INC. | $51.75 | 2021-2022 | |
| Pfizer INC. | $42.98 | 2022-2023 | |
| Sumitomo Pharma America, INC. | $42.84 | 2025 | Gemtesa |
| Merck Sharp & Dohme LLC | $40.75 | 2019 | |
| Baxter Healthcare | $24.68 | 2025 | Perclot |
| Boston Scientific Corporation | $17.15 | 2019 | |
| Bard Access Systems, INC. | $11.81 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrea Wang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.